膝下旁路术中动脉与静脉同种异体移植物的评估
本回顾性研究纳入2008至2018年因危重肢体缺血、无自体静脉可用而接受膝下动脉重建的111例患者(静脉移植物63例、动脉移植物48例)。中位随访27.8个月,动脉移植物组一期通畅率在6、12、18个月分别为65.9%、44.1%、44.1%,静脉移植物组分别为55.6%、46.0%、33.2%,两组一期通畅率差异显著(P=0.049)。选择动脉移植物而非静脉移植物是一期通畅率的独立保护因素(HR=0.43,P=0.003)。移植物类型不影响大截肢或全因死亡。
要点
- 动脉移植物组与静脉移植物组的一期通畅率差异显著(P=0.049)。
- 选择动脉移植物是一期通畅率的独立保护因素(HR=0.43,P=0.003)。
- 移植物类型不影响大截肢(HR=1.20)或全因死亡(HR=0.88)。
核心结论
- 同种异体移植物的性质似乎影响膝下动脉重建的通畅率,但不影响疾病进程。
- 需要性能优良、能解决感染问题的替代移植物。
研究设计与样本
- 回顾性研究,纳入2008至2018年因危重肢体缺血、无自体静脉可用而接受膝下动脉重建并使用静脉或动脉同种异体移植物的患者。
- 排除因移植物感染而接受翻修手术的患者。
- 共纳入111例患者(静脉移植物63例,动脉移植物48例),其中108例接受膝下旁路术。
- 中位随访时间为27.8个月(15.6-37.4)。
主要发现
- 动脉移植物组一期通畅率在6、12、18个月分别为65.9%(43.7-81.0)、44.1%(24.2-62.3)、44.1%(24.2-62.3)。
- 静脉移植物组一期通畅率在6、12、18个月分别为55.6%(40.0-68.6)、46.0%(30.6-60.2)、33.2%(18.2-49.0)。
- 两组一期通畅率差异显著(P=0.049)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autologous saphenous vein is the preferred conduit for below-the-knee bypasses in patients with critical limb-threatening ischemia. Alternative graft must be considered for patients without (autologous saphenous vein). The aim of this article is to evaluate the mid-term performance of arterial allograft (AA) and venous allograft (VA) used as alternative conduits. METHODS: This retrospective study included patients with critical limb-threatening ischemia, with or without a history of homolateral femoropopliteal bypass, and no autologous veins were available who underwent infrainguinal arterial reconstructions using VA or AA from 2008 to 2018. Patients undergoing revision operations for infected bypasses were excluded. Primary patency (PP), primary assisted patency, secondary patency, major amputation, and death from any cause were the endpoints. For each event, a set of analyses were performed. RESULTS: Overall, 111 patients (63 VAs and 48 AAs) were included, with 108 having below-the-knee bypass. The median follow-up time was 27.8 months (15.6-37.4). The difference in PP between the 2 allograft types was significant (P = 0.049), with 65.9% (43.7-81.0), 44.1% (24.2-62.3), and 44.1% (24.2-62.3) in the AA group, respectively, at 6, 12, and 18 months, whereas 55.6% (40.0-68.6), 46.0% (30.6-60.2), and 33.2% (18.2-49.0) in the VA group. The choice of an AA over a VA was an independent factor associated with patency (for PP: hazard ratio [HR] = 0.43 [0.24-0.75], P = 0.003); primary assisted patency: HR = 0.52 (0.30-0.89], P = 0.018; and secondary patency: HR = 0.49 (0.27-0.88), P = 0.016. The allograft type did not affect either the incidence of major amputation or death from any cause (respectively, HR = 1.20 [0.49-2.93], and 0.88 [0.37-2.14]). CONCLUSIONS: The nature of the allograft appears to influence the patency of infrainguinal reconstruction, but not the course of the disease. Performant alternative grafts answering infectious issues are needed.
引用
- Deflandre C, Lopez B, Patterson BO, et al. Evaluation of Arterial and Venous Allografts in Subinguinal Bypasses. Ann Vasc Surg. 2022. PMID: 36202325. doi:10.1016/j.avsg.2022.09.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。